SEC FORM 4

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Forman Darcy

(Last)

(First)

(Middle)

3411 SILVERSIDE RD, TATNALL BLDG #104

(Street)

WILMINGTON

19810

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Science 37 Holdings, Inc. [ SNCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Delivery Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/06/2021		A		42,381	A	⁽¹⁾	42,381	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$0.4	10/06/2021		A		93,602		⁽²⁾	01/22/2030	Common Stock	93,602	⁽¹⁾	93,602	D
Stock Option	$0.28	10/06/2021		A		136,147		⁽³⁾	06/07/2030	Common Stock	136,147	⁽¹⁾	136,147	D
Stock Option	$0.82	10/06/2021		A		136,147		⁽⁴⁾	01/20/2031	Common Stock	136,147	⁽¹⁾	136,147	D

Explanation of Responses:

1. Pursuant to the business combination of LifeSci Acquisition II Corp and Science 37, Inc. ("Old Science 37"), as contemplated by that certain agreement and plan of merger, dated May 6, 2021 (the "Merger Agreement"), (a) each share of common stock of Old Science 37 outstanding immediately prior to the effective time of the business combination was converted into approximately 1.8153 shares of the Issuer's Common Stock, (b) (the "Conversion Ratio"); and (b) each outstanding stock option of Old Science 37 was converted into a corresponding option to purchase shares of the Issuer's Common Stock as adjusted for the Conversion Ratio

2. Stock Option is currently vested and exercisable as to 17,019 of the underlying shares, and the remaining shares will vest in equal monthly installments until fully vested on January 6, 2024, subject to the executive's continued service through the applicable vesting date.

3. Stock Option is currently vested and exercisable as to 45,382 of the underlying shares, and the remaining shares will vest in equal monthly installments until fully vested on June 5, 2024, subject to the executive's continued service through the applicable vesting date.

4. Represents an option vesting with respect to 25% of the shares subject to the option on the first anniversary of the vesting start date, 1/21/2021, and with respect to 1/48th of the shares subject to the option on each monthly anniversary of the applicable vesting start date thereafter, subject to the executive's continued service through the applicable vesting date.

	/s/ Christine Pellizzari, Attorney-in-Fact for Darcy Forman	10/08/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 4: Forman Darcy was granted 42,381 shares